ABBISKO CAYMAN DL-00001 (F:8ZD) — Market Cap & Net Worth
Market Cap & Net Worth: ABBISKO CAYMAN DL-00001 (8ZD)
ABBISKO CAYMAN DL-00001 (F:8ZD) has a market capitalization of $915.66 Million (€783.21 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #9492 globally and #1160 in its home market, demonstrating a -7.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ABBISKO CAYMAN DL-00001's stock price €1.40 by its total outstanding shares 659753350 (659.75 Million).
ABBISKO CAYMAN DL-00001 Market Cap History: 2021 to 2026
ABBISKO CAYMAN DL-00001's market capitalization history from 2021 to 2026. Data shows growth from $744.32 Million to $1.08 Billion (3.79% CAGR).
ABBISKO CAYMAN DL-00001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ABBISKO CAYMAN DL-00001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 8ZD by Market Capitalization
Companies near ABBISKO CAYMAN DL-00001 in the global market cap rankings as of May 5, 2026.
Key companies related to ABBISKO CAYMAN DL-00001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
ABBISKO CAYMAN DL-00001 Historical Marketcap From 2021 to 2026
Between 2021 and today, ABBISKO CAYMAN DL-00001's market cap moved from $744.32 Million to $ 1.08 Billion, with a yearly change of 3.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.08 Billion | +2.19% |
| 2025 | €1.06 Billion | +160.95% |
| 2024 | €404.94 Million | +24.41% |
| 2023 | €325.50 Million | +6.57% |
| 2022 | €305.44 Million | -58.96% |
| 2021 | €744.32 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of ABBISKO CAYMAN DL-00001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $915.66 Million USD |
| MoneyControl | $915.66 Million USD |
| MarketWatch | $915.66 Million USD |
| marketcap.company | $915.66 Million USD |
| Reuters | $915.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ABBISKO CAYMAN DL-00001
Abbisko Cayman Limited engages in the research and development of pharmaceutical products in the People's Republic of China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor in NDA/commercial trial for the treatment of tenosynovial giant cell tumors, as well as chronic graft versus host disease and solid tumors. It is also developing pivotal tri… Read more